Advertisement

Clinical Rheumatology

, Volume 38, Issue 2, pp 495–502 | Cite as

Serum interleukin-37 level and interleukin-37 gene polymorphism in patients with Behçet disease

  • Selcan ÖzgüçlüEmail author
  • Türker Duman
  • Funda Seher Özalp Ateş
  • Orhan Küçükşahin
  • Sevgi Çolak
  • Ümit Ölmez
Original Article
  • 149 Downloads

Abstract

Behçet’s disease (BD) is a chronic inflammatory disease. The etiopathogenesis of BD is not well understood and several cytokines and genetic factors have been investigated. Interleukin (IL)-37, which a member of IL-1 family is an anti-inflammatory cytokine. The aim of the study was to analyze serum IL-37 level and IL-37 gene polymorphisms to assess its possible role in BD. Two hundred twenty-three patients with BD and 80 healthy controls (HC) were enrolled. Serum IL-37 level was measured using an enzyme-linked immunosorbent assay (ELISA). Deoksiribo Nucleic acids (DNA) were extracted using a genomic DNA isolation kit. Single nucleotide polymorphism (SNP) of IL-37 gene (rs3811047) was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR/RFLP) methods. Serum IL-37 level was not significantly different in BD and HC (p > 0.05). Serum IL-37 level was not associated with the disease activity (p > 0.05). However, its level was higher in mucocutaneous involvement compared with systemic involvement (p = 0.002) and HC (p = 0.005). IL-37 gene polymorphisms were similar in BD and HC (p > 0.05). IL-37 may play a role in the etiopathogenesis of BD by contributing to manifestation with more moderate clinical symptoms.

Keywords

Behçet’s disease Cytokine Gene polymorphism Interleukin-37 

Notes

Funding information

This study received financial assistance from the Ankara University Scientific Research Project Coordination Unit.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Bouali E, Kaabachi W, Hamzaoui A, Hamzaoui K (2015) Interleukin-37 expression is decreased in Behçet’s disease and is associated with inflammation. Immunol Lett 167(2):87–94.  https://doi.org/10.1016/j.imlet.2015.08.001 CrossRefGoogle Scholar
  2. 2.
    Kacem O, Kaabachi W, Dhifallah IB, Hamzaoui A, Hamzaoui K (2018) Elevated expression of TSLP and IL-33 in Behçet’s disease skin lesions: IL-37 alleviate inflammatory effect of TSLP. Clin Immunol 192:14–19.  https://doi.org/10.1016/j.clim.2018.03.016 CrossRefGoogle Scholar
  3. 3.
    İnal EE, Rüstemoğlu A, İnanır A, Ekinci D, Gül Ü, Yiğit S, Ateş Ö (2015) Associations of rs4810485 and rs1883832 polymorphisms of CD40 gene with susceptibility and clinical findings of Behçet’s disease. Rheumatol Int 35(5):837–843.  https://doi.org/10.1007/s00296-014-3171-3 CrossRefGoogle Scholar
  4. 4.
    Ye Z, Wang C, Kijlstra A, Zhou X, Yang P (2014) A possible role for interleukin 37 in the pathogenesis of Behçet’s disease. Curr Mol Med 14:535–542CrossRefGoogle Scholar
  5. 5.
    Dinarello CA, Nold-Petry C, Nold M, Fujita M, Li S, Kim S, Bufler P (2016) Suppression of innate inflammation and immunity by interleukin-37. Eur J Immunol 46(5):1067–1081.  https://doi.org/10.1002/eji.201545828 CrossRefGoogle Scholar
  6. 6.
    Dinarello CA, Bufler P (2013) Interleukin-37. Semin Immunol 25(6):389–393.  https://doi.org/10.1016/j.smim.2013.10.004 CrossRefGoogle Scholar
  7. 7.
    Wang L, Quan Y, Yue Y, Heng X, Che F (2018) Interleukin-37: a crucial cytokine with multiple roles in disease and potentially clinical therapy. Oncol Lett 15(4):4711–4719.  https://doi.org/10.3892/ol.2018.7982 Google Scholar
  8. 8.
    Liu H, Zheng R, Wang P, Yang H, He X, Ji Q, Bai W, Chen H, Chen J, Peng W, Liu S, Liu Z, Ge B (2017) IL-37 confers protection against mycobacterial infection involving suppressing inflammation and modulating T cell activation. PLoS One 12(1):e0169922.  https://doi.org/10.1371/journal.pone.0169922 CrossRefGoogle Scholar
  9. 9.
    Shi LP, He Y, Liu ZD (2013) Correlation between single nucleotide polymorphism of rs 3811047 in IL-1 F7 gene and rheumatoid arthritis susceptibility among Han population in central plains of China. Asian Pac J Trop Med 6(1):73–75.  https://doi.org/10.1016/S1995-7645(12)60204-1 CrossRefGoogle Scholar
  10. 10.
    Pan F, Liao F, Xia G, Ge R, Mei Y, Tang X, Pan H, Ye D, Zou Y, Xu S, Xu J (2010) Association of IL-1F7 gene with susceptibility to human leukocyte antigen-B27 positive ankylosing spondylitis in Han Chinese population. Clin Chim Acta 411(1–2):124–126.  https://doi.org/10.1016/j.cca.2009.10.014 CrossRefGoogle Scholar
  11. 11.
    Tan H, Deng B, Yu H, Yang Y, Ding L, Zhang Q, Qin J, Kijlstra A, Chen R, Yang P (2016) Genetic analysis of innate immunity in Behçet’s disease identifies an association with IL-37 and IL-18RAP. Sci Rep 6:35802.  https://doi.org/10.1038/srep35802
  12. 12.
    Criteria for diagnosis of Behçet’s disease (1990) International study group for Behçet’s disease. Lancet 335(8697):1078–1080Google Scholar
  13. 13.
    Forbess C, Swearingen C, Yazici Y (2008) Behçet’s syndrome activity score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with the Behçet’s disease current activity form (BDCAF). Arthritis Rheum 58(9):854Google Scholar
  14. 14.
    Yilmaz S, Simsek I, Cinar M, Erdem H, Kose O, Yazici Y, Pay S (2013) Patient-driven assessment of disease activity in Behçet’s syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet’s syndrome activity score. Clin Exp Rheumatol 31(3):77–83Google Scholar
  15. 15.
    Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG (2012) Primer3—new capabilities and interfaces. Nucleic Acids Res 40(15): e115Google Scholar
  16. 16.
    Koressaar T, Remm M (2007) Enhancements and modifications of primer design program primer3. Bioinformatics 23(10):1289–91Google Scholar
  17. 17.
    Yin D, Naji DH, Xia Y, Li S, Bai Y, Jiang G, Zhao Y, Wang X, Huang Y, Chen S, Fa J, Tan C, Zhou M, Zhou Y, Wang L, Liu Y, Chen F, Liu J, Chen Q, Tu X, Xu C, Wang QK (2017) Genomic variant in IL-37 confers a significant risk of coronary artery disease. Sci Rep 7:42175.  https://doi.org/10.1038/srep42175
  18. 18.
    Ye Z, Wang C, Kijlstra A, Zhou X, Yang P (2014) A possible role for interleukin-37 in the pathogenesis in Behçet’s disease. Curr Mol Med 14(4):535–542CrossRefGoogle Scholar
  19. 19.
    Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, Oostingh GJ, Pfaller T, Pixner C, Posselt G, Italiani P, Nold MF, Nold-Petry CA, Bufler P, Dinarello CA (2011) IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 22(3):127–147.  https://doi.org/10.1684/ecn.2011.0288 Google Scholar
  20. 20.
    Anthoni M, Fyhrquist-Vanni N, Wolff H, Alenius H, Lauerma A (2008) Transforming growth factor-beta/Smad3 signalling regulates inflammatory responses in a murine model of contact hypersensitivity. Br J Dermatol 159(3):546–554.  https://doi.org/10.1111/j.1365-2133.2008.08696.x Google Scholar
  21. 21.
    Chi H, Liu D, Sun Y, Hu Q, Liu H, Cheng X, Ye J, Shi H, Yin Y, Liu M, Wu X, Zhou Z, Teng J, Yang C, Su Y (2018) Interleukin-37 is increased in adult-onset Still’s disease and associated with disease activity. Arthritis Res Ther 20(1):54.  https://doi.org/10.1186/s13075-018-1555-6 CrossRefGoogle Scholar
  22. 22.
    Sarhan D, Hippen KL, Lemire A, Hying S, Luo X, Lenvik T, Curtsinger J, Davis Z, Zhang B, Cooley S, Cichocki F, Blazar BR, Miller JS (2018) Adaptive NK cells resist regulatory T cell suppression driven by IL-37. Cancer Immunol Res 21:766–775.  https://doi.org/10.1158/2326-6066.CIR-17-0498 CrossRefGoogle Scholar
  23. 23.
    Lİn XY, Guo XJ, He YZ, Hou SF, Zhu HB, Cheng Y, Nan Z (2018) Association between interleukin 37 (rs3811047) polymorphism and multiple autoimmune diseases in a Chinese population: a PRISMA-compliant meta-analysis. Medicine 97 (15): e0386.  https://doi.org/10.1097/MD.0000000000010386

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Selcan Özgüçlü
    • 1
    Email author
  • Türker Duman
    • 2
  • Funda Seher Özalp Ateş
    • 3
  • Orhan Küçükşahin
    • 4
  • Sevgi Çolak
    • 5
  • Ümit Ölmez
    • 5
  1. 1.Immunology and AllergyAnkara Dışkapı Yıldırım Beyazıt Education and Research HospitalAnkaraTurkey
  2. 2.Faculty of Science, BiologyAnkara UniversityAnkaraTurkey
  3. 3.BiostatisticsAnkara University School of MedicineAnkaraTurkey
  4. 4.RheumatologyAnkara Liv HospitalAnkaraTurkey
  5. 5.Immunology and AllergyAnkara University School of MedicineAnkaraTurkey

Personalised recommendations